Alpha1-antitrypsin replacement therapy controls fibromyalgia symptoms in 2 patients with PI ZZ alpha1-antitrypsin deficiency.
Two Spanish sisters with alpha1-antitrypsin (AAT) deficiency and fibromyalgia (FM) started AAT replacement therapy with commercial alpha1-antitrypsin infusions in 1992. They both experienced a rapid, progressive, and constant control of their FM symptoms during the next 6 years (1992-98). However, in 1998, treatment of both patients was affected by the worldwide commercial shortage of AAT replacement therapy; replacement therapy infusions were halted for about 4-6 consecutive months every year for 5 years. As a result, we observed a striking recurrence of FM symptoms. Equally striking was the total disappearance of these symptoms when AAT replacement therapy infusions were resumed.
Blanco
Ignacio
I
Department of Internal Medicine, Respiratory Diseases Branch, Hospital Valle del Nalón, Asturias, Spain. ignacio.blanco@sespa.princast.es
Canto
Hortensia
H
de Serres
Frederick Joseph
FJ
Fernandez-Bustillo
Enrique
E
Rodríguez
Maria Carmen
MC
D000328:Adult; D005260:Female; D005356:Fibromyalgia / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010375:Pedigree; D035781:Siblings; D000515:alpha 1-Antitrypsin / Q000627:therapeutic use*; D019896:alpha 1-Antitrypsin Deficiency / Q000150:complications / Q000188:drug therapy* / Q000235:genetics*
D000515:alpha 1-Antitrypsin